Abstract:Background In China multidrug-resistant bacteria pose a considerable threat to public health. Antimicrobial resistance has weakened the effectiveness of many medicines widely used today. Thus, discovering new antibacterial drugs is paramount in the effort to treat emerging drug-resistant bacteria. Methods Eravacycline, tigecycline and other clinical routine antibiotics were tested by reference broth micro-dilution method against 336 different strains collected from 11 teaching hospitals in China between 2012 and 2016. These isolates included Enterobacteriaceae , non-fermentative, Staphylococcus spp., Enterococcus, and a number of fastidious organisms. The strains involved in this study possess the most important drug resistance characteristics currently known in China. Drug resistant bacteria such as those producing extended spectrum β-lactamases (ESBL) and carbapenemases (KPC-2 and NDM-1), and those exhibiting colistin resistance ( mcr -1) and tigecycline were included in this study. Additionally, methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-resistant enterococci (VRE), β-lactamase positive Haemophilus influenzae , and penicillin resistant S treptococcus pneumoniae (PRSP) were also included. Results Eravacycline exhibited good efficacy against all the strains tested, especially for organisms with ESBLs, carbapenemases, and mcr -1 gene compared with tigecycline and other antibiotics tested. The MIC values of eravacycline against carbapenemase producing Enterobacteriaceae and OXA-23-producing A. baumannii were much lower than the MIC values of other antibiotics. MRSA, VRE, β-lactamase positive Haemophilus influenza , and PRSP were sensitive to eravacycline in every strain tested. Furthermore, in most strains tested, the MICs of eravacycline were two to four-fold lower than the MICs of tigecycline. Conclusions Eravacycline has shown potent antibacterial activity against common and clinically important antibiotic-resistant pathogens. The MIC distribution of eravacycline was generally lower than that of tigecycline which demonstrates that this new drug is potentially more effective than the existing medications.

Study of in vitro bactericidal activity and resistance mutant of doripenem

In vitro antibacterial activity of doripenem

Investigation of antibacteriocidal activity of domestic meropenem on β-lacta-mases-producing gram negativ bacilli in vitro

In vitro activity of flomoxef and comparators against Escherichia coli, Klebsiella pneumoniae and Proteus mirabilis producing extended-spectrum β-lactamases in China

Study on the antibacterial activity of three carbapenems to the strains isolated from ICU

National Epidemiology of Carbapenem-Resistant and Extensively Drug-Resistant Gram-negative Bacteria Isolated from Blood Samples in China in 2013.

In Vivo Activity of Doripenem in the Experimental Model of Mouse Septicemia Infected by Bacteria

Effect of Doripenem on Pseudomonas aeruginosa Biofilm Formation and the Quorum Sensing System

Pharmacokinetics and Safety of Doripenem in Healthy Chinese Subjects and Monte Carlo Dosing Simulations.

Resistance of the Carbapenems and Homology Analysis of Pseudomonas Aeruginosa in 28 Hospitals in China

In Vitro Efficacy of Doripenem against Pseudomonas aeruginosa and Acinetobacter baumannii by E-Test

In vitro activities of Eravacycline against 336 isolates collected from 2012 to 2016 from 11 teaching hospitals in China

Evaluation of Phenotypic Tests for Detection of Metallo-β-Lactamase-Producing Pseudomonas Aeruginosa Strains in China

Mohnarin Report of 2011: Monitoring of Bcterial Resistance Intensive Care Unit

In vitro antibacterial activity of three agents of carbapenems

In Vitro Activity of Imipenem/Relebactam Against Enterobacteriaceae Isolates Obtained from Intra-abdominal, Respiratory Tract, and Urinary Tract Infections in China: Study for Monitoring Antimicrobial Resistance Trends (SMART), 2015–2018

Comparing in vitro antibacterial behaviors of carbapenems against Pseudomonas aeruginosa

In vitro antibacterial activity of rifampicin in combination with imipenem, meropenem and doripenem against multidrug-resistant clinical isolates of Pseudomonas aeruginosa

Antimicrobial Resistance among Clinical Isolates from the Chinese Meropenem Surveillance Study (cmss), 2003-2008

In vitro activities of 16 antimicrobial agents against Gram-negative bacteria from six teaching hospitals in China.

Susceptibility of Cefiderocol and Other Antibiotics Against Carbapenem-Resistant, Gram-negative Bacteria